TABLE 1.
Comparison of studies on iatrogenic Creutzfeldt-Jakob disease (iCJD) and Aβ deposition. AD: Alzheimer disease; GH: growth hormone; NA: not addressed in the study; Nr: number. * Indicates that these cases were included in Study 2 also.
| Study |
Study 1 |
Study 2 |
Study 3 |
Study 4 |
|---|---|---|---|---|
| Type of iCJD | Pituitary-derived GH | Dura mater | Dura mater | Dura mater |
| Number of iCJD cases examined | 8 | 7 | 2* | 16 |
| Nr. of iCJD with parenchymal Aβ deposits | 4 + 2 focal | 5 | 2* | 13 |
| Distinct morphology or distribution of parenchymal Aβ | NA | NA | Yes | Subpial accumulation emphasized. Morphology of parenchymal plaques not commented. |
| Nr. of iCJD with CAA | 3 + 1 focal | 5 | 2* | 11 |
| Cadaveric tissue examined | No | No | Yes | No |
| Non-cadaveric tissue examined | Yes: pituitary (55 samples) | No | Yes: dura mater (84 samples) | No |
| AD related tau pathology | No | No | No | Yes - details not provided |
| Genetic aspects | APOE + AD genes | NA | APOE + AD genes | APOE |
| Statistical difference when compared to sCJD | Yes | Yes | NA | Yes |
| Age of iCJD cases with parenchymal Aβ | 4th decade to 51 | 28–63 | 28, 33 | 35–81 |
| Age of iCJD cases with CAA | 5th decade to 51 | 28–63 | 28, 33 | 35–81 |
| Age of cases < 40 y with parenchymal Aβ deposits | 36 (focal) | 28, 33 | 28, 33 | 35, 39 |
| Age of cases < 40 y with CAA | – | 28, 33 | 28, 33 | 35, 39 |
| Clinical phenotype | CJD | CJD | CJD | CJD |
| Reference | 25 | 27 | 28 | 29 |